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Abstract: 
Introduction: Cetuximab, an epidermal growth factor (EGFR) inhibitor has radio sensitizing activity 
for locoregionally, advanced head and neck cancer (LAHNC). The drug is either used in combination 
with radiotherapy or in combination with other chemotherapeutic drugs.  
Case Presentation: A 35-year-old male patient diagnosed with cancer of tongue atloco regional stage 
who had previously undergone hemiglossectomy was treated with TPF (docetaxel, cisplatin and 5-
fluorouracil) as induction therapy(ICT)followed by concurrent local radiation therapy (RT) and 
cetuximab for 6weeks.The first recurrence appeared 4 years after the surgery, which was treated with 
RT along with standard treatment with cetuximab for 6weeks.Second recurrence was treated with 
cetuximab in combination with cisplatin and docetaxel. The patient survived for 8 years since he began 
his treatment. 
Conclusion: Cetuximab in combination with RT and other chemotherapeutic drugs can offer a longer 
survival in patients with both recurrent, locally advanced and metastatic squamous cell carcinoma of 
head and neck cancer. 
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Introduction 
Head and neck cancer (HNC) is the sixth most common cancer worldwide with more than 550,000 
cases reported annually [1].The treatment of locally advanced HNC (LAHNC) usually involves a 
combination of surgery, chemotherapy and radiotherapy (RT).RT in addition to chemotherapy with 
concurrent cisplatin (CRT) is considered to be the most efficacious treatment option for SCCHN. 
However, it is often associated with acute and chronic toxicities [2]. 
 Cetuximab, a chimeric monoclonal antibody of the immunoglobulin G1 class, an EGFR 
inhibitor isa critical target in the treatment of SCCHN that is overexpressed in >90% of patients with 
SCCHN. [3]. Cetuximab in combination with RT and chemotherapeutic drugs has demonstrated 
benefit for advanced as well as recurrent/metastatic SCCHN(R/M SCCHN) [4]. Cetuximab is 
efficacious as an add-on therapy and also as a monotherapy. When used as a single agent, it exhibits a 
cytostatic effect [3]. 
 For patients with R/M SCCHN, international guidelines such as National Comprehensive 
Cancer Network Clinical (NCCN) Practice Guidelines and European Head and Neck Society (EHNS), 
European Society for Medical Oncology (ESMO) European Society for Radiotherapy and Oncology 
(ESTRO) recommend combination therapy with cetuximab as the first line treatment that results in a 
longer survival of the patients [5, 6].  
 Here, we report the case of a patient withSCCHN who initially had LASCCHN and later had 
R/M SCCHN. The patient was treated with cetuximab combination therapy. 
Case Report 
A 35-year-old male patient presented with complaints of swelling in left neck and induration of tongue 
since 5 days. Physical examination showed the presence of lateral border tongue lesion, indurated 
anteriorly with two large medial neck nodes and a node on the left side. He underwent Computer 
Tomography (CT), which showed a subtle increase in the bulk of left side of tongue with left sided 
cervical adenopathy. Figure 1 shows the CT results of the patient at the time of admission. 
 The results from FNAC confirmed the presence of numerous mature squamous cells with 
heavy infiltration of polymorphonu clear leucocytes and few multinucleate giant cells. In view of 
strong clinical suspicion patient underwent a biopsy, which revealed SCC. He underwent 
hemiglossectomyand lymph node resection on the left side.  The patient had a lesion of size 3.5 
cmx2.8cm with thickness of 1.3cm. Histopathology showedmoderately differentiated carcinoma 
(WHO pT4a N2) with infiltrating margins and the presence of 6/28 lymph nodes from level I and II 
with necrosis pericapsular infiltraton. After surgery, he was started with two cycles of chemotherapy 
with TPF, followed by concurrent localRT  and cetuximab for 6weeks.No evidence of tumor was 
found after cytoscopic examinations and MRI studies. Thus, no further therapy (including 
chemotherapy) was recommended. 
 The patient exhibited satisfactory recovery and remained asymptomatic for four years after 
which he developed an ulcer on the tongue and was readmitted (first recurrence). The patient was 
initially treated surgically and then he started the RT along with standard treatment with cetuximabfor 
6weeks. 
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He was asymptomatic for two years. During follow up, his MRI (Figure 2) revealed recurrence on 
contralateral side of tongue. The patient underwent resection again and was treated with a single cycle 
of chemotherapy for 6 weeks along with cetuximab for 12weeks. 
 In 10 months, the patient developed a mass in hypopharynx. The patient refused to undergo 
surgery after discussion with a multidisciplinary team of cancer specialists and was directly 
administered a treatment regimen comprising of docetaxel40mg weekly for 12 doses, cetuximab 
weekly for 12 doses and an injection of cisplatin 50mg every alternate week for 6 doses. Of the 
12weekly chemotherapy cycles recommended, the patient completed 8 weekly doses of above 
treatment for 5 months. The patient was further kept on palliative care at home. Due to progression of 
disease leading to multi-organdys function, the patient could not survive and died after 16 months of 
stopping treatment. Overall, the patient survived for 8 years since he began treatment in 
August 2007.  
Discussion 
Cancer like SCCHN may present with locally advanced (LA) stage III or IV disease andare usually 
treated with combined-modality therapies. Over the last 30 years, TPF as induction chemotherapy has 
been widely used for the management of patients with LA SCCHN. The results reported in the TAX 
323 and TAX 324 trials indicate that the TPF regimen (docetaxel, cisplatin and 5-fluorouracil) 
improves overall survival (OS) as compared with the PF regimen (cisplatin and 5-fluorouracil) 
[7].Cetuximab has shown beneficial results for the initial treatment of LA potentially curable disease. 
Studies by Bonner et al; showed that the median duration of locoregional control was 24.4 months 
among patients treated with cetuximab plus RT and 14.9 months among those given RT alone. At 54 
months of follow up, the median duration of OS was 49.0 months among patients treated with 
combined therapy and 29.3 months among those treated with RT alone. Survival rates at 2 years (62 % 
vs. 55 %) and at 3 years (55 % vs. 45 %) also favored the combination regimen (p=0.05 for the 
comparison at 3years) [2, 8]. 
Data from several studies suggest that the combination of cetuximab with RT shows better survival 
and locoregional disease control associated in patients with SCCHN [3, 4, 8]. For R/M SCCHN, 
cetuximab along with chemotherapy followed by cetuximab maintenance monotherapy until 
progression is the gold standard first line treatment [9]. 
 The EXTREME trial showed that the addition of cetuximabto platinum-5-fluorouracil 
improved the response rate and progression free survival (PFS) and OS. No evidence of recurrence 
was observed till 6 weeks, when the patient was first administered cetuximab in combination with 
chemotherapy and RT, and thus no further therapy was advised. This is primarily because cetuximab 
and RT have a significant benefit in locoregional control as compared with RT alone. The patient 
might have improved with the use of Cetuximab and RT [8]. 
 For almost 4 years, the patient remained asymptomatic. The first recurrence was managed 
with cetuximaband RT after resection that showed satisfactory results. The second recurrence was 
managed by cetuximab and chemotherapy followed by resection. However, it has been observed in 
various recurrent cases of HNC, the duration of treatment is often not compatible with expected 
survival [10]. Overall, the patient could survive for around 8 years since the treatment began. 
Conclusion 
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Cetuximab when given in combination with RT or used in combination with platins or with other 
chemotherapeutic drugs for management offers a survival advantage. In the advanced setting, 
treatment with cetuximab is recommended until disease progression or unacceptable toxicity. 
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Figures 
 
 
Figure 1 CT ReportofOropharynx: At the Time of Admissionon 29th May 2007 
Observations: Subtle increase in the bulk of left side of tongue with left sided cervical adenopathy. Few enlarged 
nodes in the submental and left supraclavicular region 
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Figure 2  MRI Report Before Treatment:3rd May 2013 
Observation: Recurrence was seen on contra lateral side of tongue. 
 
